Anti-Acetyl-CoA Carboxylase Monoclonal Antibody for WB, IP, ELISA - Q13085 / O00763

Core Product Specifications and Parameters

Biological Background: Acetyl-CoA Carboxylase 1 Function and Localization

• Acetyl-CoA carboxylase 1 (ACC1) is a cytosolic, biotin-dependent enzyme that catalyzes the ATP-dependent carboxylation of acetyl-CoA to malonyl-CoA, the first and rate-limiting step of de novo fatty acid biosynthesis. Related references: PMID:20457939, PMID:20952656, PMID:29899443
• The reaction proceeds in two steps: ATP-dependent carboxylation of the biotin prosthetic group on the biotin carboxyl carrier (BCC) domain, followed by transfer of the carboxyl group to acetyl-CoA.
• ACC1 is a multifunctional enzyme with biotin carboxylase (BC), biotin carboxyl carrier protein (BCCP), and carboxyltransferase (CT) domains, enabling its complex catalytic activity.
• Subcellular localization is primarily cytoplasmic and cytosolic, consistent with its role in cytosolic fatty acid synthesis.
• Tissue expression: ACC1 is expressed in brain, placenta, skeletal muscle, renal, pancreatic, and adipose tissues; expression is low in pulmonary tissue and not detected in the liver.
• The enzyme is tightly regulated by phosphorylation (e.g., by AMPK), allosteric effectors (citrate activation, palmitoyl-CoA inhibition), and alternative promoter usage, underscoring its central role in metabolic control.
• ACC2 (encoded by ACACB) is a mitochondrial isoform that generates malonyl-CoA to inhibit carnitine palmitoyltransferase I, regulating fatty acid oxidation; the antibody may recognize both ACC1 and ACC2 due to sequence homology.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 500–600 of human ACC1 (NP_942133.1), a region likely shared with ACC2; consider validating isoform specificity in the relevant sample system.
• For WB, due to the high molecular weight of ACC1 (265 kDa) and ACC2 (276 kDa), use low-percentage SDS-PAGE gels (e.g., 6–8%) and extended transfer times; include prestained high-molecular-weight markers.
• Verify the antibody’s performance in your species and application; while validated in human, mouse, and rat, cross-reactivity in other species or assay formats should be empirically confirmed.
• For IP, optimize antibody concentration and use appropriate bead systems (e.g., protein A/G); consider the impact of biotinylation or endogenous biotin on detection.
• In ELISA, pair this antibody with a suitable ACC detection reagent; test specificity with recombinant ACC1 or ACC2 protein controls.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio empowers diagnostic manufacturers and researchers with end-to-end access to high-quality IVD raw materials, from monoclonal antibodies like this anti-ACC clone to validated antibody pairs and bulk ancillary reagents. Whether you require rare target sourcing for metabolic disorder panels or optimized workflows for fatty acid research, our integrated supply chain ensures reliable, scalable delivery. Partner with CamelBio to streamline your development from concept to clinic.